Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham
July 11, 2024
Medical Diagnostics & Screening
-
-
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
July 9, 2024
-
Mainz Biomed Provides Half Year 2024 Corporate Update
July 2, 2024
-
23andMe Launches New Genetic Report on Bipolar Disorder
June 5, 2024
-
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
June 3, 2024
-
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements
May 22, 2024
-
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 20, 2024
-
OpGen Announced 1-for-10 Reverse Stock Split
May 16, 2024
-
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 10, 2024
-
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
May 7, 2024
-
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
April 25, 2024
-
Mainz Biomed Reports Full Year 2023 Financial Results
April 9, 2024
-
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
March 19, 2024
-
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 11, 2024
-
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
March 5, 2024
-
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
February 27, 2024